

## RECENT PUBLICATIONS OF THE RESEARCH GROUP

### 1. **Affinity Purification and Comparative Biosensor Analysis of Citrulline-Peptide-Specific Antibodies in Rheumatoid Arthritis.**

Szarka E, Aradi P, Huber K, Pozsgay J, Végh L, Magyar A, Gyulai G, Nagy G, Rojkovich B, Kiss É, Hudecz F, Sármay G.

Int J Mol Sci. 2018 Jan 22;19(1). pii: E326. doi: 10.3390/ijms19010326.

### 2. **Antigen-specific immunotherapies in rheumatic diseases.**

Pozsgay J, Szekanecz Z, Sármay G.

Nat Rev Rheumatol. 2017 Sep;13(9):525-537. doi: 10.1038/nrrheum.2017.107.

### 3. **Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy.**

Bankó Z, Pozsgay J, Gáti T, Rojkovich B, Ujfalussy I, Sármay G.

Clin Immunol. 2017 Nov;184:63-69. doi: 10.1016/j.clim.2017.05.012.

### 4. **Induction and Differentiation of IL-10-Producing Regulatory B Cells from Healthy Blood Donors and Rheumatoid Arthritis Patients.**

Bankó Z, Pozsgay J, Szili D, Tóth M, Gáti T, Nagy G, Rojkovich B, Sármay G.

J Immunol. 2017 Feb 15;198(4):1512-1520. doi: 10.4049/jimmunol.1600218.

### 5. **MZ B cells migrate in a T-bet dependent manner and might contribute to the remission of collagen-induced arthritis by the secretion of IL-10.**

Huber K, Sármay G, Kövesdi D.

Eur J Immunol. 2016 Sep;46(9):2239-46. doi: 10.1002/eji.201546248.

### 6. **In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles.**

Pozsgay J, Babos F, Uray K, Magyar A, Gyulai G, Kiss É, Nagy G, Rojkovich B, Hudecz F, Sármay G.

Arthritis Res Ther. 2016 Jan 16;18:15. doi: 10.1186/s13075-016-0918-0.

### 7. **Synthetic Peptide-Based ELISA and ELISpot Assay for Identifying Autoantibody Epitopes.**

Pozsgay J, Szarka E, Huber K, Babos F, Magyar A, Hudecz F, Sarmay G.

Methods Mol Biol. 2016;1352:223-33. doi: 10.1007/978-1-4939-3037-1\_17.

**8. Recognition of new citrulline-containing peptide epitopes by autoantibodies produced in vivo and in vitro by B cells of rheumatoid arthritis patients.**

Szarka E, Babos F, Magyar A, Huber K, Szittner Z, Papp K, Prechl J, Pozsgay J, Neer Z, Ádori M, Nagy G, Rojkovich B, Gáti T, Kelemen J, Baka Z, Brózik M, Pazár B, Poór G, Hudecz F, Sármay G.

Immunology. 2014 Feb;141(2):181-91. doi: 10.1111/imm.12175.

**9. Role of N- or C-terminal biotinylation in autoantibody recognition of citrullin containing filaggrin epitope peptides in rheumatoid arthritis.**

Babos F, Szarka E, Nagy G, Majer Z, Sármay G, Magyar A, Hudecz F.

Bioconjug Chem. 2013 May 15;24(5):817-27. doi: 10.1021/bc400073z.

**10. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin.**

Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, **Sarmay** G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G.

J Clin Invest. 2012 May;122(5):1791-802. doi: 10.1172/JCI60975.